Physician profile
Claudio E Vincenty
NPI 1285604793
$6,563.55
in general payments reported to CMS, 2019-2025
26 companies · $1,542 in 2025
The $1,542 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,025 · 2020: $435 · 2021: $1,378 · 2022: $885 · 2023: $719 · 2024: $579 · 2025: $1,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,285 · Consulting Fee: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,284.92 |
| Consulting Fee | $555.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,587.27 | 2021-2025 | Inceptiv, Intellis Adaptivestim, Vanta Adaptivestim |
| Abbott Laboratories | $1,392.30 | 2021-2023 | Proclaim, Eterna |
| Boston Scientific Corporation | $1,018.29 | 2021-2025 | Na, Wavewriter Alpha Prime 16, Infinion 16 |
| Medtronic USA, INC. | $710.28 | 2019-2020 | |
| Relievant Medsystems, INC. | $391.30 | 2020-2022 | |
| Abbvie INC. | $371.24 | 2023-2025 | Botox, Ubrelvy, Qulipta |
| Amgen INC. | $225.13 | 2019-2022 | |
| Allergan, INC. | $162.57 | 2019-2021 | |
| Painteq LLC | $134.75 | 2023-2024 | Painteq |
| Si-Bone, INC. | $83.28 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.75 | 2019-2024 | Relistor |
| Tersera Therapeutics LLC | $61.06 | 2019 | |
| Biocompatibles, INC. | $50.00 | 2019 | |
| Nevro Corp. | $44.34 | 2019-2024 | Senza |
| Vertos Medical, INC. | $40.22 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $27.76 | 2019 | |
| Medtronic Vascular, INC. | $26.87 | 2019 | |
| Depuy Synthes Sales INC. | $26.39 | 2023 | Monovisc, Orthovisc |
| Biotronik Nro, INC. | $23.25 | 2025 | Prospera |
| Azurity Pharmaceuticals, INC. | $22.72 | 2023 | Horizant |
| Stimwave Technologies Incorporated | $20.00 | 2019 | |
| Pacira Therapeutics, INC. | $18.39 | 2019 | |
| Lundbeck LLC | $17.75 | 2023 | Vyepti |
| Merz North America, INC. | $16.60 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.28 | 2023 | Quviviq |
| Spr Therapeutics, INC | $13.76 | 2023 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudio Vincenty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.